{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:26:22Z","timestamp":1792520782572,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T00:00:00Z","timestamp":1440460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.vaccine.2015.08.056","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T01:00:13Z","timestamp":1440810013000},"page":"5406-5414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats"],"prefix":"10.1016","volume":"33","author":[{"given":"Myra N.","family":"Widjojoatmodjo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lies","family":"Bogaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Meek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jort","family":"Vellinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Custers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Rado\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.vaccine.2015.08.056_bib0195","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jama.282.15.1440","article-title":"Bronchiolitis-associated hospitalizations among US children: 1980\u20131996","volume":"282","author":"Shay","year":"1999","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.vaccine.2015.08.056_bib0200","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2015.08.056_bib0205","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"issue":"9725","key":"10.1016\/j.vaccine.2015.08.056_bib0210","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.08.056_bib0215","doi-asserted-by":"crossref","first-page":"B209","DOI":"10.1016\/j.vaccine.2012.11.106","article-title":"Strategic priorities for respiratory syncytial virus (RSV) vaccine development","volume":"31","author":"Anderson","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.08.056_bib0220","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol Rev"},{"issue":"10","key":"10.1016\/j.vaccine.2015.08.056_bib0225","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1586\/erv.11.120","article-title":"Respiratory syncytial virus vaccine development","volume":"10","author":"Hurwitz","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2015.08.056_bib0230","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.08.056_bib0235","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1128\/JVI.68.8.5321-5325.1994","article-title":"Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10","volume":"68","author":"Connors","year":"1994","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.08.056_bib0240","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/JCM.26.8.1595-1597.1988","article-title":"Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity","volume":"26","author":"Murphy","year":"1988","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.08.056_bib0245","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/hum.2014.007","article-title":"Challenges in manufacturing adenoviral vectors for global vaccine product deployment","volume":"25","author":"Vellinga","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2015.08.056_bib0250","doi-asserted-by":"crossref","first-page":"e44115","DOI":"10.1371\/journal.pone.0044115","article-title":"Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species","volume":"7","author":"Zahn","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2015.08.056_bib0255","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","article-title":"The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2: 7A, and 12","volume":"36","author":"Maizel","year":"1968","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2015.08.056_bib0260","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/hum.1996.7.2-215","article-title":"Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors","volume":"7","author":"Fallaux","year":"1996","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2015.08.056_bib0265","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J Gen Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.08.056_bib0270","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1128\/CVI.00311-10","article-title":"The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert","volume":"17","author":"Radosevic","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.08.056_bib0275","first-page":"1385","article-title":"Pulmonary lesions in primary respiratory syncytial virus infection: reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus)","volume":"79","author":"Prince","year":"1999","journal-title":"Lab Invest"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2015.08.056_bib0280","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1099\/0022-1317-82-12-2881","article-title":"Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine","volume":"82","author":"Prince","year":"2001","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.08.056_bib0285","first-page":"771","article-title":"The pathogenesis of respiratory syncytial virus infection in cotton rats","volume":"93","author":"Prince","year":"1978","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.08.056_bib0290","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1258\/002367702320389026","article-title":"Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases","volume":"36","author":"Niewiesk","year":"2002","journal-title":"Lab Anim"},{"issue":"23","key":"10.1016\/j.vaccine.2015.08.056_bib0295","doi-asserted-by":"crossref","first-page":"12601","DOI":"10.1128\/JVI.01036-09","article-title":"Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus","volume":"83","author":"Kohlmann","year":"2009","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.08.056_bib0300","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.bbrc.2009.02.075","article-title":"Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB\/c mice","volume":"381","author":"Fu","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.vaccine.2015.08.056_bib0305","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1128\/JVI.03194-13","article-title":"Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model","volume":"88","author":"Kim","year":"2014","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.08.056_bib0310","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/mt.2013.142","article-title":"Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation","volume":"22","author":"Johnson","year":"2013","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2015.08.056_bib0315","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.pcl.2013.04.007","article-title":"Nasal obstruction in newborns","volume":"60","author":"Gnagi","year":"2013","journal-title":"Pediatr Clin North Am"},{"issue":"24","key":"10.1016\/j.vaccine.2015.08.056_bib0320","doi-asserted-by":"crossref","first-page":"13156","DOI":"10.1128\/JVI.77.24.13156-13160.2003","article-title":"Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant","volume":"77","author":"Prince","year":"2003","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.08.056_bib0325","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","article-title":"Development of motavizumab: an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract","volume":"368","author":"Wu","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2015.08.056_bib0330","doi-asserted-by":"crossref","unstructured":"The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998, 102(3 Pt 1), 531\u2013537.","DOI":"10.1542\/peds.102.3.531"},{"issue":"4","key":"10.1016\/j.vaccine.2015.08.056_bib0335","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.coviro.2013.05.005","article-title":"Protective and dysregulated T cell immunity in RSV infection","volume":"3","author":"Openshaw","year":"2013","journal-title":"Curr Opin Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.08.056_bib0340","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/erv.13.11","article-title":"Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets","volume":"12","author":"de Cassan","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2015.08.056_bib0345","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/JCM.01249-06","article-title":"Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa","volume":"44","author":"Thorner","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"12","key":"10.1016\/j.vaccine.2015.08.056_bib0350","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/509258","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector","volume":"194","author":"Catanzaro","year":"2006","journal-title":"J Infect Dis"},{"issue":"32","key":"10.1016\/j.vaccine.2015.08.056_bib0355","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2015.08.056_bib0360","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.4161\/hv.26038","article-title":"Randomized: placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults","volume":"9","author":"Creech","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2015.08.056_bib0365","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/infdis\/jis671","article-title":"Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)","volume":"207","author":"Barouch","year":"2013","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2015.08.056_bib0370","doi-asserted-by":"crossref","first-page":"e78679","DOI":"10.1371\/journal.pone.0078679","article-title":"A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"Ouedraogo","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2015.08.056_bib0375","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2015.08.056_bib0380","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1128\/JVI.00512-12","article-title":"Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys","volume":"86","author":"Liu","year":"2012","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15011846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15011846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T18:57:05Z","timestamp":1599505025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15011846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":38,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0264410X15011846"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.08.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.08.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}